糖尿病
医学
疾病
2型糖尿病
血糖性
心力衰竭
糖尿病性心肌病
重症监护医学
内科学
生物信息学
心肌病
内分泌学
生物
标识
DOI:10.1016/j.vph.2023.107247
摘要
Vascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the cardiorenal potential of medications such as glucagon-like peptide1-receptor agonists (GLP1RA) and sodium-glucose transporter 2-inhibitors (SGLT2i). Even greater are the expectations for the new dual glucose-dependent insulinotropic-peptide (GIP) and GLP1 agonists. Along with these new diabetes drugs, opportunities are now provided for renal protecting agents like finerenone. Finally, new pharmacologic venues are currently under investigation for treating diabetic cardiomyopathy, a cause for heart failure in diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI